BAYER AG NA O.N.
Commented by Stefan Feulner on June 7th, 2021 | 09:37 CEST
Bayer, Defence Therapeutics, MorphoSys - A paradigm shift in biotechnology
The search for a vaccine against the Coronavirus brought biotechnology back into the focus of investors last year. Companies such as BioNTech or CureVac were able to multiply in this regard. In 2020, the biotech sector in Germany raised a record sum of EUR 3 billion, and the trend is rising sharply. The fight against incurable diseases and the development of important innovations such as vaccines, cancer therapies, or sustainable products lift the segment into higher realms and offer attractive investment opportunities.
Read
Commented by Stefan Feulner on May 28th, 2021 | 08:40 CEST
Bayer, Osino Resources, Xiaomi - Here is what happens now
Pharmaceutical giant Bayer fails once again in court with settlement proceedings and is now calling for a new plan. A court ruling means a liberation blow for another company, which significantly increases the prospects for the future. Future prospects are also rosy for the precious metal gold due to fundamental conditions such as fear of inflation, loose monetary policy, and continued low interest rates. At the current level, there are excellent long-term entry opportunities with healthy profits.
Read
Commented by Nico Popp on May 26th, 2021 | 08:15 CEST
BioNTech, PsyBio, Bayer: The opportunities of tomorrow
Even after the pandemic, there will be no "business as usual" in the healthcare system, as shown by a survey conducted a few months ago by the Barmer Institute for Health Research. The scientists surveyed called for far-reaching reforms. In addition to billing and uniform rules, digitization could also be a key to meaningful reforms. Innovative drugs also play a role when it comes to treating Covid-19 and concomitant diseases.
Read
Commented by Carsten Mainitz on May 25th, 2021 | 11:35 CEST
Bayer, Saturn Oil + Gas, Deutsche Lufthansa - All the ingredients for a price fireworks display!
Information moves prices. Sometimes up, sometimes down, and sometimes information seems to "bounce off" - ignored or misinterpreted by market participants. It is easier said than done to correctly classify the information in relation to the long-term perspective of a company. Thus, as seen last week with Bayer and Deutsche Lufthansa, a short-term price dampener is a good opportunity to enter the market. But also, information that is complex in detail and must first be "understood", offers the chance to make a real bargain. Canadian oil and gas producer Saturn is a case in point. The Company is moving into new dimensions with an acquisition, and according to the latest analyst report, the stock has the potential to triple in value. Where will you buy?
Read
Commented by Armin Schulz on April 19th, 2021 | 08:10 CEST
Plug Power, Desert Gold, Bayer - Shares with opportunities despite all-time highs?
Almost all indices are near their all-time highs. No wonder, given the expansive monetary policy and the associated inflation expectations. Commodity prices, in particular, are seeing a sharp rise. Thursday, gold was able to break the resistance area at USD 1,750. Despite this positive environment, however, some stocks are far from their all-time high. We will take a closer look at these today.
Read
Commented by André Will-Laudien on March 29th, 2021 | 08:15 CEST
Cardiol Therapeutics, Bayer, Formycon: These pharma stocks could explode!
According to official statistics, diseases of the cardiovascular system, such as heart failure, coronary heart disease or myocardial infarction, are the No.1 cause of death in Germany. With 18.2 million deaths, they represented the most common cause of death worldwide in 2019. Thus, on a global average, a good 30% of all deaths are attributable to cardiovascular disease. In Europe, more than 4 million people die each year due to such a disease, 1.4 million of whom are younger than 75. But there are many other dangers to our health. Reason enough to take a closer look.
Read
Commented by Stefan Feulner on March 16th, 2021 | 07:16 CET
Bayer, Cardiol Therapeutics, Xiaomi - Biotech: Blockbuster potential here!
Germany is leading the race for a vaccine against the coronavirus With two companies - BioNTech and CureVac. The biotech industry is currently experiencing a growth spurt that will continue over the next few years, if not decades. In Germany alone, EUR 7 billion is invested annually in research and development. The goal is to develop new therapies to prevent, alleviate and cure diseases. The opportunity for disproportionate share price gains by investing in a company at an early stage of research is gigantic.
Read
Commented by Carsten Mainitz on March 15th, 2021 | 09:03 CET
Bayer, dynaCERT, JinkoSolar - green performance stars!
Sustainable investing has developed from a "nice to have" to a "must-have." Many empirical studies have also shown that investors who invest "green" do not have to forego returns. On the contrary, there are indications that a skillful weighting of ESG factors - these stand for Environment, Social, Governance - can improve the risk-return ratio. We show you three ESG stocks with which you will outperform in the truest sense of the word!
Read
Commented by Stefan Feulner on February 9th, 2021 | 08:00 CET
CureVac, Cardiol Therapeutics, Bayer - roaring profits!
The race for the best and most effective vaccine is in full swing. After BioNTech and its partner Pfizer, Moderna and AstraZeneca were approved in Europe, but there are always obstacles. Over the weekend, for example, South Africa announced that it is forgoing the AstraZeneca vaccine for the time being. The background to this is its supposedly lower efficacy with the B.1.351 virus mutation. Somewhat unnoticed, another vaccine manufacturer is moving into pole position through innovative collaborations.
Read
Commented by Stefan Feulner on February 5th, 2021 | 12:22 CET
Deutsche Bank, wallstreet:online, Bayer - The return of the giants!
The dinosaurs of the German economy report good news. Deutsche Bank has made it into the black for six years, and Bayer AG is making progress in settling the Monsanto debacle. Among online brokers, the wheat was separated from the chaff last week and we present you with an online broker you can trust!
Read